The FDA has accepted Belite Bio’s application for tinlarebant and [...]

Aravind Eye Care System and Alcon have launched a new [...]

Atsena Therapeutics has received EMA orphan designation for two gene [...]

ATSN-401, Atsena Therapeutics’ investigational gene therapy for Stargardt disease, has [...]

Atsena Therapeutics has dosed the first patient in the Phase [...]

PulseSight Therapeutics has completed dosing in its Phase 1 clinical [...]

Complement Therapeutics GmbH (CTx) has received clearance from the FDA [...]